Skip to content

Postoperative Nausea and Vomiting following Intrathecal Dexamethasone versus Intravenous Dexamethasone on caesarean delivery with intrathecal morphine, A randomized, double blinded clinical trial

Postoperative Nausea and Vomiting following Intrathecal Dexamethasone versus Intravenous Dexamethasone on caesarean delivery with intrathecal morphine, A randomized, double blinded clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
PACTR
Registry ID
PACTR202507584655206
Enrollment
102
Registered
2025-07-03
Start date
2021-08-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post operative nausea and vomiting Anaesthesia

Interventions

Sponsors

Aswan University Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Women aged 18 - 35 years, 38 weeks pregnant or more Scheduled for elective cesarean delivery ASA class II.

Exclusion criteria

Exclusion criteria: ASA III & IV as pregnancy-induced complications like eclampsia Acute obstetric hemorrhage, Fetal distress, Cord prolapse, Mothers having compromised fetus, Allergy to morphine or dexamethasone, Body mass index (BMI) >35 kg/m2 History of hyperemesis gravidarum or GERD during the pregnancy. parturients who required general anesthesia due to failure of spinal anesthesia

Design outcomes

Primary

MeasureTime frame
Levels of maternal satisfaction at 24 hours was assessed through a 5-point Likert scale (1 = completely dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, and 5 = completely satisfied)

Secondary

MeasureTime frame
Postoperative nausea and vomiting (PONV) was assessed using the simplified PONV impact scale(SPONVIS) [7]. Episodes with a severity score =5 were recorded, and clinically significant vomiting was treated with 4 mg IV ondansetron, repeated after 12 hours if persistent;Analgesia duration was the time from intrathecal injection to first pain requiring rescue analgesia. Pain severity was measured using a 10-cm visual analogue scale (VAS; 0 = no pain, 10 = most severe), categorized as mild (<4), moderate (4–6), or severe (7–10). Breakthrough pain received 1 g IV acetaminophen, with total doses recorded.;Itching was rated on an ordinal scale: 0 (no itch), 1 (mild), 2 (moderate), 3 (severe)

Countries

Egypt

Contacts

Public ContactMohamed Kamel

Aswan University Hospital

drmohamedkamel85@gmail.com+201014761523

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026